Lee Danner & Bass Inc. Reduces Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Lee Danner & Bass Inc. decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,631 shares of the medical equipment provider’s stock after selling 120 shares during the period. Lee Danner & Bass Inc.’s holdings in Zimmer Biomet were worth $320,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Vontobel Holding Ltd. lifted its position in Zimmer Biomet by 4.5% in the third quarter. Vontobel Holding Ltd. now owns 8,540 shares of the medical equipment provider’s stock valued at $958,000 after purchasing an additional 366 shares during the period. IFP Advisors Inc lifted its position in Zimmer Biomet by 20.4% in the third quarter. IFP Advisors Inc now owns 2,763 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 469 shares during the period. PFG Advisors lifted its position in Zimmer Biomet by 7.5% in the third quarter. PFG Advisors now owns 1,815 shares of the medical equipment provider’s stock valued at $204,000 after purchasing an additional 126 shares during the period. Ziegler Capital Management LLC lifted its position in Zimmer Biomet by 10.2% in the third quarter. Ziegler Capital Management LLC now owns 30,915 shares of the medical equipment provider’s stock valued at $3,469,000 after purchasing an additional 2,852 shares during the period. Finally, Montecito Bank & Trust lifted its position in Zimmer Biomet by 4.6% in the third quarter. Montecito Bank & Trust now owns 2,272 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent analyst reports. Barclays raised their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. Citigroup boosted their price target on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Raymond James boosted their price target on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. boosted their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a research note on Friday, February 23rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $139.39.

Get Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Trading Up 1.1 %

Shares of ZBH opened at $120.78 on Tuesday. The stock has a fifty day moving average of $126.23 and a two-hundred day moving average of $119.37. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The company has a market capitalization of $24.82 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 2.19 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. Zimmer Biomet’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.88 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.70% of the company’s stock.

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.